» Articles » PMID: 3922455

Elevated Adenosine Deaminase and Purine Nucleoside Phosphorylase Activity in Peripheral Blood Null Lymphocytes from Patients with Acquired Immune Deficiency Syndrome

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1985 Jun 1
PMID 3922455
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The purine metabolic enzymes adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) are important in lymphocyte differentiation, and genetic deficiencies of either enzyme have been associated with hereditary immunodeficiency states. Both ADA and PNP activity were measured in null cell-enriched and T cell-enriched peripheral blood lymphocytes from 16 patients with the acquired immune deficiency syndrome (AIDS), seven patients with the AIDS-related symptom complex (ARC), and seven asymptomatic homosexuals. ADA activity in nmol/10(6) lymphocytes/h was significantly elevated in null lymphocytes from AIDS (161 +/- 12) as compared with 23 healthy heterosexual controls (127 +/- 8;P less than .025). PNP activity was also significantly increased in null lymphocytes from AIDS patients (96 +/- 10;P less than .005) as well as those from ARC patients (84 +/- 11:P less than .025) relative to controls (61 +/- 5). No significant differences in enzyme activity were noted in T cell-enriched cells in any group. Along with elevated enzyme activity, AIDS patients had small yet significant increases in the percentages of HLA-DR (P less than .025), terminal deoxynucleotidyl transferase (TdT) (P less than .0001), and peanut agglutinin receptor (P less than .0001) positive lymphocytes in the null fraction compared with controls. TdT-positive cells appeared morphologically as large lymphoblasts with irregular nuclei. The data imply that the cellular immune deficiency in AIDS is not a result of deficiencies in lymphocyte ADA or PNP activity, but is more likely associated with an increase in an immature and/or activated lymphocyte subset.

Citing Articles

Artificial Neural Network-Based Study Predicts GS-441524 as a Potential Inhibitor of SARS-CoV-2 Activator Protein Furin: a Polypharmacology Approach.

Dhanalakshmi M, Das K, Pandya M, Shah S, Gadnayak A, Dave S Appl Biochem Biotechnol. 2022; 194(10):4511-4529.

PMID: 35507249 PMC: 9066385. DOI: 10.1007/s12010-022-03928-2.


Serum adenosine deaminase levels are associated with diabetic kidney disease in type 2 diabetic patients.

Lu C, Liu W, Ge X, Xu F Endocr Connect. 2021; 10(9):973-979.

PMID: 34319903 PMC: 8428043. DOI: 10.1530/EC-21-0306.


The relationship between adenosine deaminase and heart rate-corrected QT interval in type 2 diabetic patients.

Lu C, Ge X, Wang Y, Su J, Wang X, Zhang D Endocr Connect. 2021; 10(8):894-901.

PMID: 34261041 PMC: 8346184. DOI: 10.1530/EC-21-0199.


Serum adenosine deaminase activity and coronary artery disease: a retrospective case-control study based on 9929 participants.

Xuan C, Tian Q, Zhang S, Li H, Tian T, Zhao P Ther Adv Chronic Dis. 2019; 10:2040622319891539.

PMID: 31839921 PMC: 6900608. DOI: 10.1177/2040622319891539.


Adenosine signaling and adenosine deaminase regulation of immune responses: impact on the immunopathogenesis of HIV infection.

Passos D, Bernardes V, da Silva J, Schetinger M, Leal D Purinergic Signal. 2018; 14(4):309-320.

PMID: 30097807 PMC: 6298925. DOI: 10.1007/s11302-018-9619-2.